Back

ONS 2024 - 49th Annual Congress of Oncology Nursing Society

Apr 24 - Apr 28, 2024 | Washington, DCUS

LARVOL is not affiliated with 49th Annual Congress of Oncology Nursing Society and all trademarks, logos, and brand names are property of their respective owners

Top Trials
Top Trials has no data

Showing 26 abstracts linked to Trials

RS72 - Patient-Targeted Education (ePRO-E) to Increase ePRO Uptake Within an Alliance Clinical Trial (A221805-SI1)

  • E-Poster

RS158 - Exploring the Role of a Dedicated Research Nurse in a National Cancer Institute Community Oncology Research Program (NCORP) Alliance Study

  • Late-Breaking, Poster

I16 - Safety of tepotinib + osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) with mesenchymal–epithelial transition (MET) amplification following first-line osimertinib: INSIGHT 2 primary analysis

  • Poster

I39 - Post-progression and safety outcomes with first-line (1L) amivantamab plus lazertinib versus osimertinib in patients with advanced non-small cell lung cancer (NSCLC) with common EGFR mutations: Implications for best management practices

  • Late-Breaking, Poster

I20 - The Effect of Prior Docetaxel Treatment in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving Apalutamide plus Androgen Deprivation Therapy (TITAN Study)

  • Late-Breaking, Poster

I41 - Impact of a Rash Management Protocol on Incidence and Severity of Rash with Apalutamide Patients with High-Risk Localized Prostate Cancer (Apa-RP Study)

  • Late-Breaking, Poster

I33 - Safety outcomes of subcutaneous nivolumab across phase 1/2 CheckMate 8KX and phase 3 Checkmate 67T studies

  • Late-Breaking, Poster

I36 - Presence of Homologous Recombination Repair Gene Mutations and Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving First Line Treatment (CAPTURE Study)

  • Late-Breaking, Poster

I17 - Treatment with Enzalutamide in Patients with High-risk Biochemically Recurrent Prostate Cancer from the EMBARK Trial: Nursing Implications

  • E-Poster

I32 - Management of adverse events associated with cabozantinib for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, or radioiodine-refractory differentiated thyroid cancer

  • Late-Breaking, Poster

I37 - Management of adverse events associated with cabozantinib plus nivolumab in advanced renal cell carcinoma

  • Late-Breaking, Poster

I26 - CARTITUDE-2 Long-Term Efficacy and Safety of Ciltacabtagene Autoleucel for Patients With Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and With Early Relapse (Cohort B)

  • Late-Breaking, Poster

I35 - Final Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Repair Gene Alterations Receiving First-Line Niraparib with Abiraterone Acetate plus Prednisone (MAGNITUDE Study)

  • Late-Breaking, Poster

I34 - Patient-Reported Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer and BRCA1/2 Mutations Receiving First-Line Niraparib with Abiraterone Acetate plus Prednisone (MAGNITUDE Study)

  • Late-Breaking, Poster

RS76 - Impact of socioeconomic disadvantage on symptom duration, treatment initiation, and survival among primary brain tumor patients: A large cohort analysis

  • Poster